Valerie Yager
Adult Health · Dolgeville, NYNPI 1558703264
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 87.7% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $7,366 and has fallen 97.7% since, to $168 in 2025. Among adult health clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 184 payments — averaging $83.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$13K
- AbbVie$480
- Viiv Healthcare Company$262
- Astellas Pharma US Inc$204
- Merck$202
- Johnson & Johnson$107
- plus $641 from 15 others
What the payments were for
- Speaking & faculty fees$8,12053%
- Travel & lodging$3,83025%
- Food & beverage$3,22921%
- Education$2051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 86 | $13,487 |
| AbbVie | 31 | $480 |
| Viiv Healthcare Company | 11 | $262 |
| Astellas Pharma US Inc | 5 | $204 |
| Merck | 9 | $202 |
| Johnson & Johnson | 3 | $107 |
| GSK | 5 | $84 |
| Lilly USA, LLC | 5 | $73 |
| Insmed, Inc. | 4 | $71 |
| Biohaven Pharmaceuticals, Inc. | 3 | $63 |
| Pfizer | 4 | $63 |
| Ferring Pharmaceuticals Inc. | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $45 |
| AstraZeneca | 3 | $40 |
| Amgen | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $27 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Abbott | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| IBSA Pharma Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,384 in reported general payments places this provider in the 95th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 374 | $1,477,884 |
| EpclusaSofosbuvir/Velpatasvir | 16 | $380,319 |
| JulucaDolutegravir/Rilpivirine | 76 | $270,913 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 34 | $153,385 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 34 | $121,810 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 29 | $102,254 |
| TivicayDolutegravir Sodium | 32 | $70,885 |
| PrezcobixDarunavir/Cobicistat | 21 | $47,621 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $43,857 |
| DovatoDolutegravir Sodium/Lamivudine | 13 | $41,120 |
| IsentressRaltegravir Potassium | 21 | $40,592 |
| Darunavir | 14 | $20,350 |
| PifeltroDoravirine | 11 | $19,383 |
| EmtrivaEmtricitabine | 13 | $7,019 |
| JanuviaSitagliptin Phosphate | 11 | $5,828 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Epclusa, Genvoya, Descovy | $13,487 | $2,055,445441 claims |
| Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Dovato | $262 | $504,727155 claims |
| MerckIsentress, Pifeltro, Januvia | $202 | $65,80343 claims |
| Johnson & JohnsonPrezcobix | $107 | $47,62121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,828 adult health providers in New York.
Other adult health in Dolgeville
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Mary CiechoskiBuffalo$200K
- Jennifer FioriniGlens Falls$151K
- Katelyn McCormackAmherst$131K
- Maria Gigante-BaggettEast Syracuse$92K
- Jane PattersonRochester$66K
- Alyson HartyNew York$65K
- Danielle BrunoPlainview$61K
- Julie PlantamuraPort Jefferson Station$60K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.